NGM Biopharmaceuticals has patented a method for reducing blood glucose levels in humans by combining a glucagon receptor antagonist with an immunotherapeutic agent. The method involves administering specific antibodies targeting GCGR and anti-CD3 antibodies. GlobalData’s report on NGM Biopharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights NGM Biopharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on NGM Biopharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. NGM Biopharmaceuticals's grant share as of January 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment method using glucagon receptor antagonist and immunotherapeutic agent

Source: United States Patent and Trademark Office (USPTO). Credit: NGM Biopharmaceuticals Inc

A recently granted patent (Publication Number: US11845802B2) discloses a method for reducing blood glucose levels in human subjects by administering a combination of a glucagon receptor (GCGR) antagonist and an immunotherapeutic agent. The GCGR antagonist is specified as an antibody that binds to human GCGR, while the immunotherapeutic agent is an anti-CD3 antibody. The patent outlines specific amino acid sequences for the antibody's heavy and light chain variable regions, emphasizing the importance of sequence identity for efficacy.

Furthermore, the patent details the potential outcomes of the method, including increased C-peptide levels in the blood and pancreas, reduced HbA1c levels, and decreased supplemental insulin use in the treated subjects. Additionally, the method allows for the administration of other therapeutic agents alongside the GCGR antagonist and immunotherapeutic agent, such as diabetes or hyperglycemia drugs, obesity drugs, appetite suppressants, or weight loss drugs. The patent also mentions the use of humanized antibodies and specific antibody classes like IgG1, IgG2, and IgG4 for both the GCGR antagonist and anti-CD3 antibody. Overall, the patent provides a detailed framework for a novel method aimed at treating hyperglycemia and potentially increasing beta cell mass or regeneration in human subjects through a combination of specific antibodies.

To know more about GlobalData’s detailed insights on NGM Biopharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies